108598 20260113221444.0 doi 10.1183/13993003.04283-2020 sideral 124810 ART-2021-124810 eng Rubio-Gracia, Jorge Universidad de Zaragoza (orcid)0000-0002-4769-7154 Point-of-care lung ultrasound assessment for risk stratification and therapy guiding in COVID-19 patients. A prospective non-interventional study. 2021 Access copy available to the general public Unrestricted Background Lung ultrasound is feasible for assessing lung injury caused by coronavirus disease 2019 (COVID-19). However, the prognostic meaning and time-line changes of lung injury assessed by lung ultrasound in COVID-19 hospitalised patients are unknown. Methods Prospective cohort study designed to analyse prognostic value of lung ultrasound in COVID-19 patients by using a quantitative scale (lung ultrasound Zaragoza (LUZ)-score) during the first 72 h after admission. The primary end-point was in-hospital death and/or admission to the intensive care unit. Total length of hospital stay, increase of oxygen flow and escalation of medical treatment during the first 72 h were secondary end-points. Results 130 patients were included in the final analysis; mean±sd age was 56.7±13.5 years. Median (interquartile range) time from the beginning of symptoms to admission was 6 (4–9) days. Lung injury assessed by LUZ-score did not differ during the first 72 h (21 (16–26) points at admission versus 20 (16–27) points at 72 h; p=0.183). In univariable logistic regression analysis, estimated arterial oxygen tension/inspiratory oxygen fraction ratio (PAFI) (hazard ratio 0.99, 95% CI 0.98–0.99; p=0.027) and LUZ-score >22 points (5.45, 1.42–20.90; p=0.013) were predictors for the primary end-point. Conclusions LUZ-score is an easy, simple and fast point-of-care ultrasound tool to identify patients with severe lung injury due to COVID-19, upon admission. Baseline score is predictive of severity along the whole period of hospitalisation. The score facilitates early implementation or intensification of treatment for COVID-19 infection. LUZ-score may be combined with clinical variables (as estimated by PAFI) to further refine risk stratification. info:eu-repo/semantics/openAccess by-nc https://creativecommons.org/licenses/by-nc/4.0/deed.es 33.801 2021 RESPIRATORY SYSTEM 2 / 66 = 0.03 2021 Q1 T1 4.336 2021 Pulmonary and Respiratory Medicine 2021 Q1 Medicine (miscellaneous) 2021 Q1 18.9 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Giménez-López, Ignacio Universidad de Zaragoza (orcid)0000-0002-6043-4869 Garcés-Horna, Vanessa Universidad de Zaragoza López-Delgado, Daniel Sierra-Monzón, José Luis (orcid)0000-0002-8796-2717 Martínez-Lostao, Luis Universidad de Zaragoza (orcid)0000-0003-3043-147X Josa-Laorden, Claudia Universidad de Zaragoza (orcid)0000-0002-8328-9836 Ruiz-Laiglesia, Fernando Universidad de Zaragoza (orcid)0000-0002-5172-0388 Pérez-Calvo, Juan Ignacio Universidad de Zaragoza (orcid)0000-0003-2361-9941 Crespo-Aznarez, Silvia García-Lafuente, J. Peña Fresneda, Natacha Amores Arriaga, Beatriz Universidad de Zaragoza (orcid)0000-0001-6613-0359 Gracia-Tello, Borja (orcid)0000-0003-3248-2908 Sánchez-Marteles, Marta Universidad de Zaragoza (orcid)0000-0002-2338-7637 1012 410 Universidad de Zaragoza Dpto. Farmac.Fisiol.y Med.L.F. Área Fisiología 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 1011 566 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Inmunología 58, 3 (2021), 2004283 [9 pp.] Eur. respir. j. European respiratory journal 0903-1936 439815 http://zaguan.unizar.es/record/108598/files/texto_completo.pdf Versión publicada 2859170 http://zaguan.unizar.es/record/108598/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:108598 articulos driver 2026-01-13-22:10:36 ARTICLE